Jump to ContentJump to Main Navigation
Economic Dimensions of Personalized and Precision Medicine - Chicago Scholarship Online
Users without a subscription are not able to see the full content.

Economic Dimensions of Personalized and Precision Medicine

Ernst R. Berndt, Dana P. Goldman, and John Rowe


Advances in human genetics have begun to yield clinical benefits through the development of Precision Medicine (PM). The benefits of this innovation are promising, both through application of constitutional genetics detecting mutations that affect the risk of disease and tumor genetics, and malignancy-causing mutations susceptible to targeted therapies. While PM may ultimately be used in all aspects of medicine, to date, the most fruitful applications have been in maternal-fetal medicine and cancer. However, due to the complexity and cost of developing these innovations, and to privacy issues, ... More

Keywords: personalized medicine targeted medicine tailored medicine stratified medicine genetic testing screening insurance coverage

Bibliographic Information

Print publication date: 2019 Print ISBN-13: 9780226611068
Published to Chicago Scholarship Online: September 2019 DOI:10.7208/chicago/9780226611235.001.0001


Affiliations are at time of print publication.

Ernst R. Berndt, editor
MIT Sloan School of Management

Dana P. Goldman, editor
not available

John Rowe, editor

Show Summary Details

subscribe or login to access all content.




Ernst R. Berndt, Dana P. Goldman, and John W. Rowe

2 Therapeutic Translation of Genomic Science

Manuel Hermosilla and Jorge Lemus

3 The Value of Pharmacogenomic Information

John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson

5 Characterizing the Drug Development Pipeline for Precision Medicines

Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern

8 Physicians’ Financial Incentives to Personalize Medicine

David H. Howard, Jason Hockenberry, and Guy David

9 Economic Dimensions of Personalized and Precision Medicine in Asia

Jui-fen Rachel Lu (盧瑞芬‎), Karen Eggleston (翁笙和‎), and Joseph Tung-Chieh Chang (張東杰‎)

10 The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event

Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright